Quaternized NAMPT Inhibitor Conjugates for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-standing need for improving the tolerability and therapeutic index of NAMPT inhibitors to effectively treat disease states associated with abnormal cells that have heightened energy demands, as existing NAMPT inhibitors exhibit cytotoxicity towards normal cells.
Innovation Solution
Development of Ligand Drug Conjugates comprising a quaternized NAMPT Drug Unit covalently attached to a Ligand Unit through a self-immolative Spacer Unit, which targets abnormal cells, allowing for controlled release of the NAMPT inhibitor within these cells to deplete intracellular NAD+ levels, thereby inhibiting cancer and inflammatory cell metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NAMPT inhibitors are administered as free drugs to deplete intracellular NAD+ levels in abnormal cells, then the therapeutic effect on cancer and inflammatory diseases is improved, but cytotoxicity towards normal cells increases
Solution Approach 1:
The invention divides the therapeutic agent into two separate components: a targeting ligand that specifically binds to abnormal cells and a NAMPT inhibitor drug. This segmentation allows the drug to be delivered selectively to abnormal cells through the ligand, reducing exposure and cytotoxicity to normal cells while maintaining therapeutic efficacy in the target cells.
Solution Approach 2:
The ligand acts as an intermediary that mediates the delivery of the NAMPT inhibitor to abnormal cells. The ligand binds to specific receptors on abnormal cells and facilitates the internalization and release of the drug, ensuring that the cytotoxic NAMPT inhibitor is delivered only to the intended target cells and not to normal cells.
2Productivity
If NAMPT inhibitors are used to treat disease states with heightened energy demands, then the metabolic activity of abnormal cells is inhibited, but the therapeutic index is reduced due to cytotoxicity
Solution Approach 1:
The invention applies local quality by making the drug delivery system cell-type specific. The ligand component is designed to recognize and bind only to abnormal cells with heightened metabolic activity, thereby concentrating the metabolic inhibition effect locally in the target cells while sparing normal cells with different metabolic characteristics, thus improving the therapeutic index.
Solution Approach 2:
By segmenting the therapeutic agent into a targeting ligand and a NAMPT inhibitor, the invention achieves local metabolic inhibition in abnormal cells only. This segmentation allows the drug to exert its productivity-enhancing metabolic inhibition effect specifically where needed, while the ligand ensures selective delivery that protects normal cells, thereby improving the overall therapeutic index.
3Quantity of substance
If free NAMPT inhibitors are administered to deplete NAD+ in abnormal cells, then intracellular ATP production is disrupted, but normal cells are also affected causing side effects
Solution Approach 1:
The ligand serves as an intermediary that directs the NAMPT inhibitor to abnormal cells specifically. This intermediary mechanism ensures that NAD+ depletion occurs only in the target abnormal cells that express the ligand's receptor, preventing the drug from reaching and affecting normal cells, thereby eliminating side effects while maintaining effective NAD+ depletion in the disease state.
Solution Approach 2:
The segmented design separates the targeting function (ligand) from the NAD+ depletion function (NAMPT inhibitor). This segmentation ensures that the quantity of NAD+ depletion is concentrated in abnormal cells only, as the ligand delivers the drug selectively to these cells, preventing NAD+ depletion in normal cells and avoiding the harmful side effects associated with it.
Data Source
AI summary
Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.